MEDVi Updates QUAD Formula for Erectile Dysfunction Treatment
News related to:MEDVi · 2 min read
MEDVi, a telehealth company, has announced a significant update to its QUAD formula, a compounded prescription treatment for erectile dysfunction (ED). The new version, effective as of September 2026, replaces the previous active ingredient, PT-141, with apomorphine, marking a step forward in the company's approach to ED treatment.
QUAD now combines four key ingredients: sildenafil, tadalafil, PT-141, and L-citrulline. Sildenafil and tadalafil are well-known PDE5 inhibitors, with the latter offering a longer-lasting effect. PT-141, a novel addition, works through the central nervous system to address the desire aspect of ED. L-citrulline supports nitric-oxide-related blood flow, potentially enhancing the overall effectiveness of the treatment.
The updated formula is part of MEDVi's commitment to offering a comprehensive and convenient solution for ED. Patients can undergo a private online evaluation, followed by a review by a licensed provider. If approved, the medication is delivered directly to the patient's doorstep, ensuring privacy and convenience.
MEDVi emphasizes that the new formula is a genuine improvement over the previous version, which paired sildenafil and tadalafil with vardenafil and apomorphine. The company has confirmed that the current formula includes sildenafil, tadalafil, PT-141, and L-citrulline, and patients are advised to verify this during their evaluation and on their dispensed label.
The pricing for QUAD starts at $114 per month, with a reference price of $179 per month. MEDVi advises patients to confirm the current pricing at the time of consultation or checkout. The company also offers ongoing support, including 24/7 medical assistance and the ability to cancel the subscription at any time.
Eligibility and dosing are determined by the prescribing clinician, and patients are encouraged to disclose all current medications, including nitrates, during the intake process. MEDVi stresses that the compounded nature of QUAD means it is not FDA-approved, and patients should be aware of potential medication interactions.
The new formula is a significant update for MEDVi's QUAD treatment, reflecting the company's ongoing efforts to provide advanced and effective solutions for ED. Patients are advised to verify the current formula to ensure they receive the most up-to-date and effective treatment.